Inocras key facts
as of Oct 2026- Developer of a genome-based big data platform designed to pave the way for a new era of personalized precision medicine.
- Inocras is valued at approximately $323.0M as of Oct 2026 (last reported valuation).
- It has raised $51.7M; the latest was Later Stage VC in Jun 2025.
- Notable investors include Samsung Venture Investment, InterVest, Schmidt (South Korea), Ministry of SMEs and Startups, VNTG — 16 tracked in total.
- Status: Privately Held (backing).
Inocras's last reported valuation, Nov 2023. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch Inocras: the Monday email on marks, rounds and moves
Inocras funding rounds
No funding rounds for Inocras are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Inocras
16+Inocras valuation
Inocras's last reported valuation was $323 million in Nov 2023. No priced round, secondary trade or fund mark has surfaced since.
Inocras investors
16 investors are on record for Inocras, including Samsung Venture Investment, InterVest, Schmidt (South Korea) and Ministry of SMEs and Startups.
About Inocras
Developer of a genome-based big data platform designed to pave the way for a new era of personalized precision medicine. The company's platform offers insights through the precise interpretation of full-length genome big data, enabling clients to employ the information effectively in their operations.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2020
- Employees
- 40
- Website
- inocras.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.